Neucardin® (rh-Neuregulin-1), A Late Stage First-in-Class Therapeutic Agent for Chronic Heart Failure
Time: 10:15 am
day: Day One
Details:
- A FIC biologic with novel target MoA directly on cardiomyocytes.
- Multiple trials involving over 2000 HF patients indicated a great potential to significantly reduce mortality and reverse ventricular remodeling in target patients.
- Under US/China Phase III stage and was granted FDA fast track designation, expected to be commercialized in 2025 at the earliest
